Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Overcoming Acquired Drug Resistance to Cancer Therapies through Targeted STAT3 Inhibition
Sunanda Singh, Héctor W. Gómez, Shreya Thakkar, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 5, pp. 4722-4722
Open Access | Times Cited: 21

Showing 21 citing articles:

Multifaceted roles for BCL3 in cancer: a proto-oncogene comes of age
Gillian Seaton, Hannah Smith, Andrea Brancale, et al.
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 5
Venetoclax resistance in acute myeloid leukaemia—Clinical and biological insights
Boaz Nachmias, Shlomzion Aumann, Arnon Haran, et al.
British Journal of Haematology (2024) Vol. 204, Iss. 4, pp. 1146-1158
Open Access | Times Cited: 5
A Review of the Efficacy of Nanomaterial-Based Natural Photosensitizers to Overcome Multidrug Resistance in Cancer
Jagadeesh Rajaram, Lokesh Kumar Mende, Yaswanth Kuthati
Pharmaceutics (2024) Vol. 16, Iss. 9, pp. 1120-1120
Open Access | Times Cited: 5
Structure, function, signaling pathways and clinical therapeutics: The translational potential of STAT3 as a target for cancer therapy
Dandan Shi, Jiejing Tao, Shuli Man, et al.
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2024) Vol. 1879, Iss. 6, pp. 189207-189207
Closed Access | Times Cited: 5
Dihydrotanshinone I enhanced BRAF mutant melanoma treatment efficacy by inhibiting the STAT3/SOX2 signaling pathway
Xing Luo, Yi Duan, Jian He, et al.
Frontiers in Oncology (2025) Vol. 15
Open Access
Pathogenetic development, diagnosis and clinical therapeutic approaches for liver metastasis from colorectal cancer (Review)
Zhenhua Jin, Yin Li, Yi Hao, et al.
International Journal of Oncology (2025) Vol. 66, Iss. 3
Closed Access
Targeting the STAT3 pathway with STAT3 degraders
Zhijie Wang, Xiaotong Liao, Haiqi He, et al.
Trends in Pharmacological Sciences (2024) Vol. 45, Iss. 9, pp. 811-823
Closed Access | Times Cited: 4
The oncogenic mechanisms of the Janus kinase-signal transducer and activator of transcription pathway in digestive tract tumors
Ruihong Zhao, Zhangmin Hu, Xiaoli Zhang, et al.
Cell Communication and Signaling (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 3
Exposure of human glioblastoma cells to thimerosal inhibits the thioredoxin system and decreases tumor growth-related factors
Isabella Bramatti, Michael Aschner, Vasco Branco, et al.
Toxicology and Applied Pharmacology (2024) Vol. 484, pp. 116844-116844
Open Access | Times Cited: 3
Nano co-delivery of doxorubicin and plumbagin achieves synergistic chemotherapy of hepatocellular carcinoma
Chenyu Cao, Yifei Li, Fangzhou Shi, et al.
International Journal of Pharmaceutics (2024) Vol. 661, pp. 124424-124424
Closed Access | Times Cited: 3
MiR-383 sensitizes osteosarcoma cells to bortezomib treatment via down-regulating PSMB5
Haifan Wang, Chuanyi Bai, Xiaoqian Dang, et al.
Molecular Biology Reports (2024) Vol. 51, Iss. 1
Closed Access | Times Cited: 2
Napabucasin deactivates STAT3 and promotes mitoxantrone-mediated cGAS-STING activation for hepatocellular carcinoma chemo-immunotherapy
Lingzhi Wang, Shengnan Bi, Zhuo Li, et al.
Biomaterials (2024) Vol. 313, pp. 122766-122766
Closed Access | Times Cited: 2
Fluorinated and N-Acryloyl-Modified 3,5-Di[(E)-benzylidene]piperidin-4-one Curcuminoids for the Treatment of Pancreatic Carcinoma
Hindole Ghosh, Sangita Bhattacharyya, Rainer Schobert, et al.
Pharmaceutics (2023) Vol. 15, Iss. 7, pp. 1921-1921
Open Access | Times Cited: 6
A New IL-6 Inducing Mechanism in Cancer with new Therapeutic Possibilities
Leif Håkansson, Pontus Dunér, Erik Broströmer, et al.
(2024)
Open Access | Times Cited: 1
Nitro-fatty acids: promising agents for the development of new cancer therapeutics
Jessica Roos, Georg Manolikakes, Uwe Schlomann, et al.
Trends in Pharmacological Sciences (2024) Vol. 45, Iss. 11, pp. 1061-1080
Open Access | Times Cited: 1
Novel Therapeutic Targets in Cancers
Elena Levantini
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 19, pp. 14660-14660
Open Access | Times Cited: 4
Emerging Therapeutic Targets and Drug Resistance Mechanisms in Immunotherapy of Hematological Malignancies
Wioletta Olejarz, Grzegorz W. Basak
Cancers (2023) Vol. 15, Iss. 24, pp. 5765-5765
Open Access | Times Cited: 4
In Saccharomyces cerevisiae ρ0 Cells, UME6 Contributes to the Activation of ABC Transporter Genes and Pleiotropic Drug Resistance via RPD3 and PDR3
M. Funasaka, M Ota, Yoichi Yamada
Microbiology Research (2024) Vol. 15, Iss. 2, pp. 734-745
Open Access
STAT3 Pathways Contribute to β-HCH Interference with Anticancer Tyrosine Kinase Inhibitors
Sara Fiorini, Elisabetta Rubini, Monia Perugini, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 11, pp. 6181-6181
Open Access
A New IL-6-Inducing Mechanism in Cancer with New Therapeutic Possibilities
Leif Håkansson, Pontus Dunér, Erik Broströmer, et al.
Cancers (2024) Vol. 16, Iss. 21, pp. 3588-3588
Open Access
Acquired resistance to tyrosine kinase targeted therapy: mechanism and tackling strategies
Defa Wu, Qian Sun, Hongjun Tang, et al.
Drug Resistance Updates (2024) Vol. 78, pp. 101176-101176
Closed Access
Page 1

Scroll to top